NCT00704431View on ClinicalTrials.gov

A Study With Darapladib to Collect Tolerability Information

PHASE1CompletedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Atherosclerosis

Interventions

DRUG

SB-480848 (darapladib)

160 mg darapladib

Trial Locations (1)

19406

GSK Investigational Site, King of Prussia

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY